A Yoshioka

Summary

Affiliation: Nara Medical University
Country: Japan

Publications

  1. ncbi request reprint Safety and efficacy of a new recombinant FVIII formulated with sucrose (rFVIII-FS) in patients with haemophilia A: a long-term, multicentre clinical study in Japan
    A Yoshioka
    Department of Paediatrics, Nara Medical University, Kashihara, Nara, Japan
    Haemophilia 7:242-9. 2001
  2. ncbi request reprint Clinical evaluation of a recombinant factor VIII preparation (Kogenate) in previously untreated patients with hemophilia A
    A Yoshioka
    Department of Pediatrics, Nara Medical University, Kashihara, Japan
    Int J Hematol 78:467-74. 2003
  3. ncbi request reprint Clinical evaluation of recombinant factor VIII preparation (Kogenate) in previously treated patients with hemophilia A: descriptive meta-analysis of post-marketing study data
    A Yoshioka
    Department of Pediatrics, Nara Medical University, Kashihara, Nara, Japan
    Int J Hematol 84:158-65. 2006
  4. ncbi request reprint The measurement of low levels of factor VIII or factor IX in hemophilia A and hemophilia B plasma by clot waveform analysis and thrombin generation assay
    T Matsumoto
    Department of Pediatrics, Nara Medical University, Nara, Japan
    J Thromb Haemost 4:377-84. 2006
  5. ncbi request reprint Factor V C2 domain contains a major thrombin-binding site responsible for thrombin-catalyzed factor V activation
    H Suzuki
    Department of Pediatrics, Nara Medical University, Kashihara, Japan
    J Thromb Haemost 4:1354-60. 2006
  6. ncbi request reprint Immunological characterization of factor VIII autoantibodies in patients with acquired hemophilia A in the presence or absence of underlying disease
    T Matsumoto
    Department of Pediatrics, Nara Medical University, 840 Shijo-cho, Kashihara, Nara 634-8522, Japan
    Thromb Res 104:381-8. 2001
  7. ncbi request reprint Molecular characterization of L-amino acid oxidase from Agkistrodon halys blomhoffii with special reference to platelet aggregation
    H Takatsuka
    Department of Pediatrics, Nara Medical University, Kashihara, Japan
    Biochim Biophys Acta 1544:267-77. 2001
  8. ncbi request reprint Unresponsiveness to factor VIII inhibitor bypassing agents during haemostatic treatment for life-threatening massive bleeding in a patient with haemophilia A and a high responding inhibitor
    T Hayashi
    Department of Pediatrics, Nara Medical University, Kashihara, Nara 634 8522, Japan
    Haemophilia 10:397-400. 2004
  9. ncbi request reprint Clinical trial to investigate the pharmacokinetics, pharmacodynamics, safety, and efficacy of recombinant factor VIIa in Japanese patients with hemophilia with inhibitors
    A Shirahata
    Department of Pediatrics, University of Occupational and Environmental Health, Japan, Kitakyushu, Fukuoka
    Int J Hematol 73:517-25. 2001
  10. ncbi request reprint Enhanced low shear stress induced platelet aggregation by Shiga-like toxin 1 purified from Escherichia coli O157
    H Yagi
    Department of Second Internal Medicine, Nara Medical University, Kashihara, Japan
    Am J Hematol 66:105-15. 2001

Collaborators

Detail Information

Publications37

  1. ncbi request reprint Safety and efficacy of a new recombinant FVIII formulated with sucrose (rFVIII-FS) in patients with haemophilia A: a long-term, multicentre clinical study in Japan
    A Yoshioka
    Department of Paediatrics, Nara Medical University, Kashihara, Nara, Japan
    Haemophilia 7:242-9. 2001
    ..ELISA assay testing for antibodies to rFVIII, baby hamster kidney cell (BHK) protein, and murine IgG were all negative. These results show that rFVIII-FS is a safe and effective for long-term treatment of patients with haemophilia A...
  2. ncbi request reprint Clinical evaluation of a recombinant factor VIII preparation (Kogenate) in previously untreated patients with hemophilia A
    A Yoshioka
    Department of Pediatrics, Nara Medical University, Kashihara, Japan
    Int J Hematol 78:467-74. 2003
    ..These data indicate that Kogenate is safe and effective for the treatment of bleeding in PUPs with hemophilia A...
  3. ncbi request reprint Clinical evaluation of recombinant factor VIII preparation (Kogenate) in previously treated patients with hemophilia A: descriptive meta-analysis of post-marketing study data
    A Yoshioka
    Department of Pediatrics, Nara Medical University, Kashihara, Nara, Japan
    Int J Hematol 84:158-65. 2006
    ..1%) observed in 108 patients. Only 1 infusion was necessary in 3790 (98.3%) of these episodes. These data indicate that Kogenate is safe and very effective for the treatment of bleeding in PTPs with hemophilia A...
  4. ncbi request reprint The measurement of low levels of factor VIII or factor IX in hemophilia A and hemophilia B plasma by clot waveform analysis and thrombin generation assay
    T Matsumoto
    Department of Pediatrics, Nara Medical University, Nara, Japan
    J Thromb Haemost 4:377-84. 2006
    ..Precise assessment of clotting function is essential for monitoring of hemostatic treatment for hemophilias A and B...
  5. ncbi request reprint Factor V C2 domain contains a major thrombin-binding site responsible for thrombin-catalyzed factor V activation
    H Suzuki
    Department of Pediatrics, Nara Medical University, Kashihara, Japan
    J Thromb Haemost 4:1354-60. 2006
    ..Furthermore, the present results also suggested that thrombin has an independent binding site for FV different from that for FVIII...
  6. ncbi request reprint Immunological characterization of factor VIII autoantibodies in patients with acquired hemophilia A in the presence or absence of underlying disease
    T Matsumoto
    Department of Pediatrics, Nara Medical University, 840 Shijo-cho, Kashihara, Nara 634-8522, Japan
    Thromb Res 104:381-8. 2001
    ..IgG1 antibody reactivity was higher in Group B than in Group A. Our results suggested a close relationship between the presence of underlying disease and immunological and coagulation characteristics in acquired hemophilia A...
  7. ncbi request reprint Molecular characterization of L-amino acid oxidase from Agkistrodon halys blomhoffii with special reference to platelet aggregation
    H Takatsuka
    Department of Pediatrics, Nara Medical University, Kashihara, Japan
    Biochim Biophys Acta 1544:267-77. 2001
    ....
  8. ncbi request reprint Unresponsiveness to factor VIII inhibitor bypassing agents during haemostatic treatment for life-threatening massive bleeding in a patient with haemophilia A and a high responding inhibitor
    T Hayashi
    Department of Pediatrics, Nara Medical University, Kashihara, Nara 634 8522, Japan
    Haemophilia 10:397-400. 2004
    ..The long-term use of APCC such as FEIBA or rFVIIa, requires careful monitoring in terms of FVIII inhibitor bypassing activity as well as the tendency to DIC...
  9. ncbi request reprint Clinical trial to investigate the pharmacokinetics, pharmacodynamics, safety, and efficacy of recombinant factor VIIa in Japanese patients with hemophilia with inhibitors
    A Shirahata
    Department of Pediatrics, University of Occupational and Environmental Health, Japan, Kitakyushu, Fukuoka
    Int J Hematol 73:517-25. 2001
    ..In conclusion. rFVIIa is an effective and well-tolerated option for treatment of bleeding episodes in hemophilia patients with inhibitors...
  10. ncbi request reprint Enhanced low shear stress induced platelet aggregation by Shiga-like toxin 1 purified from Escherichia coli O157
    H Yagi
    Department of Second Internal Medicine, Nara Medical University, Kashihara, Japan
    Am J Hematol 66:105-15. 2001
    ..Taken together, these results indicate that platelets lack Gb3, and Stx1 appears to modulate platelet aggregation in an indirect fashion, presumably by the release of cytokines or chemical compounds from the target tissues...
  11. ncbi request reprint Efficacy of auxiliary partial orthotopic liver transplantation for cure of hemophilia in a canine hemophilia A model
    S Ko
    Department of Surgery, Nara Medical University, Kashihara, Nara, Japan
    Transplant Proc 37:1131-3. 2005
    ..These findings suggest the clinical feasibility and efficacy of APOLT for metabolic liver diseases...
  12. ncbi request reprint Segregation of a pure form of spastic paraplegia and NOR insertion into Xq11.2
    A Tamagaki
    Pediatric Clinic, Todaiji Seishien, Handicapped Children s Hospital, Nara, Japan
    Am J Med Genet 94:5-8. 2000
    ..Summing up these findings, it is proposed that the NOR insertion in the affected members of the family disrupted a hitherto unknown gene for a pure form of spastic paraplegia, situated at Xq11.2, and caused the disorder...
  13. doi request reprint Increase of coagulation potential in chronic spontaneous urticaria
    T Takeda
    Department of Pediatrics, Nara Medical University School of Medicine, Kashihara, Nara 634 8522, Japan
    Allergy 66:428-33. 2011
    ..However, little is known about the components of the intrinsic coagulation pathway potentially involved...
  14. ncbi request reprint Shear-dependent functions of the interaction between soluble von Willebrand factor and platelet glycoprotein Ib in mural thrombus formation on a collagen surface
    M Sugimoto
    Department of Pediatrics, Nara Medical University, Japan
    Int J Hematol 69:48-53. 1999
    ..These findings indicate that, in addition to the interaction of surface-immobilized vWF with GP Ib in platelet adhesion, the interaction of soluble vWF with GP Ib is required for secondary thrombus growth selectively at high shear rates...
  15. ncbi request reprint Disappearance of inhibitor to factor IX in a patient with severe haemophilia B and immunological characterization of the inhibitor
    Y Ohkubo
    Department of Pediatrics, Nara Medical College, Japan
    Clin Lab Haematol 10:177-85. 1988
    ..No large deletion of the factor IX gene in the patient was observed using cDNA (cVII)...
  16. doi request reprint Establishment of embryonic stem cells secreting human factor VIII for cell-based treatment of hemophilia A
    S Kasuda
    Department of Paediatrics, Nara Medical University, Kashihara, Nara, Japan
    J Thromb Haemost 6:1352-9. 2008
    ..Although various gene therapies have been attempted with the aim of eliminating the need for factor VIII replacement therapy, obstacles to their clinical application remain...
  17. ncbi request reprint Effectiveness of factor VIII infusions in haemophilia A patients with high responding inhibitors
    S Kasuda
    Department of Pediatrics, Nara Medical University, Kashihara, Nara, Japan
    Haemophilia 10:341-6. 2004
    ..Furthermore, the haemostatic response may be monitored accurately and efficiently by clot waveform analysis...
  18. ncbi request reprint Role of factor VIII C2 domain in factor VIII binding to factor Xa
    K Nogami
    Department of Pediatrics, Nara Medical University, 840 Shijo cho Kashihara City, Nara 634, Japan
    J Biol Chem 274:31000-7. 1999
    ..Our results provide the first evidence for a direct role of the C2 domain in the association between FVIII and FXa...
  19. doi request reprint Antithrombotic properties of pravastatin reducing intra-thrombus fibrin deposition under high shear blood flow conditions
    Masaaki Hamada
    Department of Regulatory Medicine for Thrombosis, Nara Medical University 840 Shijo cho, Kashihara, Nara 634 8521, Japan
    Thromb Haemost 105:313-20. 2011
    ..Shear rate-dependent antithrombotic activity may explain the favourable effect of pravastatin on the reduction in cardiovascular events that typically occur in vivo under whole blood flow conditions with high shear rates...
  20. ncbi request reprint Casein hydrolysate formula-induced liver dysfunction in a neonate with non-immunoglobulin E-mediated cow's milk allergy
    K Yada
    Department of Pediatrics, Nara Medical University School of Medicine, Kashihara, Japan
    J Investig Allergol Clin Immunol 18:67-70. 2008
    ..These observations suggest that careful attention should be paid to liver dysfunction in non-immunoglobulin E-mediated cow's milk allergy, even when hypoallergenic formula is used...
  21. ncbi request reprint [A case of postencephalitic intractable partial epilepsy with multiple brain lesions demonstrated by MRI]
    M Shibata
    Department of Pediatrics, Nara Medical University
    No To Hattatsu 29:481-7. 1997
    ..We considered this case corresponds to focal encephalitis related to "a peculiar type of post-encephalitic/encephalopathic epilepsy" reported by Awaya et al...
  22. ncbi request reprint Upshaw-Schulman syndrome revisited: a concept of congenital thrombotic thrombocytopenic purpura
    S Kinoshita
    Department of Pediatrics, Nara Medical University, Kashihara City, Japan
    Int J Hematol 74:101-8. 2001
    ..Thus, the 2 to 3 weeks of therapeutic benefit from plasma infusions will be discussed in relation to the intravascular lifetime of vWF-CPase...
  23. ncbi request reprint Angio-oedema in a neonate with IgG antibodies to parvovirus B19 following intrauterine parvovirus B19 infection
    S Miyagawa
    Department of Dermatology, Nara Medical University, Kashihara City, Nara 634, Japan
    Br J Dermatol 143:428-30. 2000
    ..Neonatal angio-oedema might be included in the clinical spectrum of parvovirus B19 infection in pregnancy...
  24. ncbi request reprint Cutaneous mastocytosis associated with a mixed germ cell tumour of the ovary: report of a case and review of the literature
    S Miyagawa
    Department of Dermatology, Nara Medical University, Kashihara City, Nara 634 8522, Japan
    Br J Dermatol 145:309-12. 2001
    ..This is the sixth report of a germ cell tumour associated with mastocytosis. c-kit receptor point mutations, including Asp816Val and Val560Gly were absent in a biopsy specimen obtained from lesional skin...
  25. ncbi request reprint Factor VIII gene analysis in Japanese CRM-positive and CRM-reduced haemophilia A patients by single-strand conformation polymorphism
    S Morichika
    Department of Paediatrics, Nara Medical University, Kashihara City, Japan
    Br J Haematol 98:901-6. 1997
    ..All the mutations are point mutations resulting in missense codons. Four mutations (Trp255Cys, Thr667Arg, Thr2245Ala and Gly2285Val) have not been described previously...
  26. ncbi request reprint Inhibition of human platelet aggregation by L-amino acid oxidase purified from Naja naja kaouthia venom
    Y Sakurai
    Department of Blood Transfusion Medicine, Nara Medical University, 840 Shijo-cho, Kashihara, Nara 634-8522, Japan
    Toxicon 39:1827-33. 2001
    ..These results indicate that K-LAO functions as an inhibitor to platelet aggregation through the formation of hydrogen peroxide. The enzyme may contribute to the development of a severe hematological disorder due to cobra envenomation...
  27. ncbi request reprint Management of haemophilia B inhibitor patients with anaphylactic reactions to FIX concentrates
    M Shibata
    Department of Pediatrics, Nara Medical University, Kashihara, Nara, Japan
    Haemophilia 9:269-71. 2003
    ..We have successfully treated three patients whose treatment with FIX had been suspended...
  28. ncbi request reprint Analysis of macrophages in urine sediments in children with IgA nephropathy
    Y Maruhashi
    Department of Pediatrics, Nara Medical University, Kashihara City, Nara, Japan
    Clin Nephrol 62:336-43. 2004
    ..To establish a more convenient and noninvasive method for estimating the degree of macrophage infiltration we examined the number of macrophages in urinary sediments...
  29. ncbi request reprint Impaired activity of plasma von Willebrand factor-cleaving protease may predict the occurrence of hepatic veno-occlusive disease after stem cell transplantation
    Y D Park
    Department of Pediatrics, Nara Medical University, Kashihara, Nara, Japan
    Bone Marrow Transplant 29:789-94. 2002
    ..These results indicate that the measurement of this enzyme activity is extremely useful in predicting the occurrence of VOD prior to a demonstration of its direct involvement in its pathogenesis...
  30. ncbi request reprint Haemostatic management of intraoral bleeding in patients with von Willebrand disease
    Y Morimoto
    Department of Dental Anesthesiology, Graduate School of Dentistry, Osaka University, Suita, Osaka, Japan
    Oral Dis 11:243-8. 2005
    ..To develop plans for the haemostatic management of intraoral bleeding in patients with von Willebrand disease (VWD)...
  31. ncbi request reprint An arginine to cysteine amino acid substitution at a critical thrombin cleavage site in a dysfunctional factor VIII molecule
    M Shima
    Scripps Clinic and Research Foundation, La Jolla, CA
    Blood 74:1612-7. 1989
    ..We conclude that the pathogenesis of hemophilia A in this patient is probably due to an arginine to cysteine substitution at a thrombin cleavage site in the FVIII heavy chain...
  32. ncbi request reprint Congenital deficiency of alpha 2-plasmin inhibitor in three sisters
    A Yoshioka
    Haemostasis 11:176-84. 1982
    ..Bleeding episodes due to deficiency of alpha 2-PI in these patients were well controlled by an antifibrinolytic agent, tranexamic acid...
  33. ncbi request reprint Blockade of NKG2D signaling prevents the development of murine CD4+ T cell-mediated colitis
    Y Ito
    Department of Gastroenterology and Hepatology, Tokyo Medical and Dental University, 1 5 45 Yushima, Bunkyo ku, Tokyo 113 8519, Japan
    Am J Physiol Gastrointest Liver Physiol 294:G199-207. 2008
    ..These findings demonstrate that NKG2D signaling pathway is critically involved in CD4(+) T cell-mediated disease progression and suggest a new therapeutic target for inflammatory bowel diseases...
  34. ncbi request reprint Excision of pseudotumour in a patient with haemophilia A and inhibitor managed with recombinant factor VIIa
    H Takedani
    Department of Orthopaedic Surgery, National Sanatorium Fukui Hospital, Kiyama, Mikata cho, Mikata gun, Fukui, Japan
    Haemophilia 10:179-82. 2004
    ..Although a spontaneous haemorrhage was observed on postoperative day 8, haemostasis was achieved by reducing the dosage interval. No adverse event occurred during the course of treatment...
  35. ncbi request reprint Specific detection of human coagulation factor IX in cynomolgus macaques
    J Mimuro
    Divisions of Cell and Molecular Medicine and Genetic Therapeutics, Center for Molecular Medicine, Jichi Medical School, Tochigi ken, Japan
    J Thromb Haemost 2:275-80. 2004
    ....
  36. ncbi request reprint Higher recovery of factor VIII (FVIII) with intermediate FVIII/von Willebrand factor concentrate than with recombinant FVIII in a haemophilia A patient with an inhibitor
    T Inoue
    Haemophilia 12:110-3. 2006
  37. ncbi request reprint Factor IX Amagasaki: a new mutation in the catalytic domain resulting in the loss of both coagulant and esterase activities
    T Miyata
    Department of Biology, Faculty of Science, Kyushu University, Fukuoka, Japan
    Biochemistry 30:11286-91. 1991
    ..This is the first report to show the experimental evidence for importance of a highly conserved Gly-142 (chymotrypsinogen numbering) located in the catalytic site of mammalian serine proteases so far known...